Weekly Eli Lilly and Company - Amylin Pharmaceuticals, Inc. Diabetes Drug Tops Sanofi-Aventis (France) Drug

NEW YORK, June 24 (Reuters) - A once-weekly diabetes drug being developed by Eli Lilly and Co (LLY.N) and Amylin Pharmaceuticals Inc (AMLN.O) was slightly better at controlling blood sugar than Sanofi-Aventis's (SASY.PA) Lantus, but led to weight loss instead of gain, according to data from a study.

Back to news